ライフサイエンスコーパス: postvaccination

1 or various exposure windows (i.e., intervals postvaccination).

2 sociated with H1N1-specific B cell responses postvaccination.

3 10 days) and long-term (6 months) protection postvaccination.

4 cted in the serological memory response 9 mo postvaccination.

5 nodes, when the animals were challenged 2 y postvaccination.

6 placebo and at 6 weeks, 1 year, and 2 years postvaccination.

7 rent increase in previously undetected types postvaccination.

8 n and for serious AEs (SAEs) through day 182 postvaccination.

9 esponses were maintained for up to 30 months postvaccination.

10 SFV Georgia 2007 isolate as early as 2 weeks postvaccination.

11 ostvaccination, and remained at 80% 80 weeks postvaccination.

12 ar, 3 years, and, when available, 6-10 years postvaccination.

13 an experiment with a challenge given 52 days postvaccination.

14 as well as lethal VEEV challenge at 8 months postvaccination.

15 ies (titer, approximately 1:6,400) by day 26 postvaccination.

16 Antiviral antibodies were not observed postvaccination.

17 d CD4(+) T-cell proliferation also increased postvaccination.

18 allenge infection after 12, 16, and 20 weeks postvaccination.

19 nated with PA pDNA were challenged >7 months postvaccination.

20 s, VZV-specific CMI was increased at 6 weeks postvaccination.

21 rates were 92%/72%, and 73% were serotested postvaccination.

22 ecombinant vaccinia viruses (rVVs) at 5 days postvaccination.

23 infection when challenge was done 2 or 12 wk postvaccination.

24 tion when infectious challenge was done 2 wk postvaccination.

25 n from acute splenomegaly as early as 1 week postvaccination.

26 ere compared with those of 40 adults 6 weeks postvaccination.

27 enged with virulent SIV(mac251), at 25 weeks postvaccination.

28 lethal parasite challenge for at least 1 mo postvaccination.

29 were challenged with RacL11 at various times postvaccination.

30 lent challenge with Brescia virus at 21 days postvaccination.

31 us AEs (SAEs) were recorded through 6 months postvaccination.

32 erse events (AEs) were recorded days 1 to 42 postvaccination.

33 cination and one due to malnutrition 70 days postvaccination.

34 as well as whole-group comparisons pre- and postvaccination.

35 period and for each year from 7 to 11 years postvaccination.

36 ccine recipients followed for up to 11 years postvaccination.

37 ease; 95% CI, 33.7-43.3; P < .0001) pre- and postvaccination.

38 gainst ASFV-G is highly effective by 28 days postvaccination.

39 P(+) cells in the muscle at days 3, 5, and 7 postvaccination.

40 s that enter the memory compartment 3 months postvaccination.

41 ated zoster vaccine efficacy through 4 years postvaccination.

42 ostvaccination and after as many as 140 days postvaccination.

43 demonstrate more robust changes pre- versus postvaccination.

44 serotypes 6B and 23F were evaluated 1 month postvaccination.

45 l 3 outcome measures from 7 through 11 years postvaccination.

46 o vaccination and at 1, 6, 12, and 18 months postvaccination.

47 equent high-dose DENV2 challenge at 19 weeks postvaccination.

48 ely to be an issue in the general population postvaccination.

49 ver 6 years and for 225 individuals pre- and postvaccination.

50 ion test (PRNT50) established that by day 62 postvaccination, 100% of animals seroconverted to DENV-1

51 ed the vaccines (prevaccination 2007-2009 vs postvaccination 2013-2016) in Sweden, where the 21 count

52 Pre- and postvaccination Ab titers did not distinguish between su

53 memory CD8(+) T cells depended on the early postvaccination action of the inflammatory chemokines CC

54 ive immune responses, both postinfection and postvaccination, although no vaccine-development program

55 tion; 95% confidence interval [CI], 32%-63%) postvaccination among <5-year-olds.

56 eometric mean concentrations (GMCs) pre- and postvaccination among all age groups targeted for vaccin

57 ethal influenza infection after only 14 days postvaccination and after as many as 140 days postvaccin

58 between the two mouse strains at 24 and 72 h postvaccination and also performed unbiased total gene e

59 10(5) or 10(6) PFU Congo Basin MPXV 30 days postvaccination and evaluating morbidity and mortality.

60 spreading, and repertoire changes that arise postvaccination and following Ag-specific immunotherapie

61 ll adverse events (AEs) from day 1 to day 42 postvaccination and for serious AEs (SAEs) through day 1

62 fornia/7/2009 virus were detected up to 4 wk postvaccination and higher in human CMV (HCMV)-seronegat

63 m pathogenic RacL11 challenge at 1 to 7 days postvaccination and increased the expression of IFN-gamm

64 Syncope is increasingly recognized postvaccination and may be associated with severe injury

65 ,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more d

66 To identify mechanisms that act early postvaccination and might predict vaccine outcome, we im

67 za vaccine died, one due to anasarca 12 days postvaccination and one due to malnutrition 70 days post

68 eutic targets to enhance antiviral responses postvaccination and postinfection.

69 tuberculosis, we examined cytokine responses postvaccination and recruitment of activated T cells and

70 chieved was tested at 6 months and at 1 year postvaccination, and mice challenged at these times rema

71 Seroprotection increased to 89% 8 weeks postvaccination, and remained at 80% 80 weeks postvaccin

72 28 days postvaccination, whereas at 21 days postvaccination, animals survived the lethal challenge b

73 wing subcutaneous RhCMV challenge at 8 weeks postvaccination, animals vaccinated with MVA-RhUL128C sh

74 who completed the vaccination series and had postvaccination anti-HBs titers available were identifie

75 All patients demonstrated an increase in postvaccination antibody and T cell responses against va

76 We also identified a gender difference in postvaccination antibody avidity (female < male subjects

77 concentrations resulted in 20% to 28% lower postvaccination antibody concentration (geometric mean r

78 Compared with mean postvaccination antibody concentrations in PV recipients

79 ernal antibody was associated with 11% lower postvaccination antibody for pertussis toxoid (GMR, 0.89

80 ual variation and build predictive models of postvaccination antibody responses.

81 and 52 younger siblings who did not undergo postvaccination antibody tests (group 2) were studied.

82 were more compliant than male patients with postvaccination antibody titer measurements.

83 One year postvaccination, antigen-specific CD8(+) T cells were re

84 significant serum antibody responses 21 days postvaccination as measured by enzyme-linked immunosorbe

85 m lethal VEEV and EEEV challenges at 1 month postvaccination as well as lethal VEEV challenge at 8 mo

86 s that expand in response to the YFV 2 weeks postvaccination (as defined by their unique T cell recep

87 cific CTL memory was maintained for 6 months postvaccination, as demonstrated by vigorous secondary C

88 Typhi: mean postvaccination bactericidal antibody titers were higher

89 >/=4-fold rise in antibody titer) at 1 month postvaccination based on serum hemagglutination inhibiti

90 escribed, with a review of the literature on postvaccination BP.

91 Postvaccination cell-mediated immune (CMI) responses hav

92 ose seen using the glcV mutant in the 22-day postvaccination challenge.

93 The postvaccination changes (n-fold) in the percentages of i

94 rriage was a useful surrogate for monitoring postvaccination changes in the incidence of pneumococcal

95 ts a pattern of reduced and lagged epidemics postvaccination, closely matching the observed dynamics.

96 layed-type hypersensitivity reactions to E75 postvaccination compared with controls (33 v 7 mm; P < .

97 tween vaccinated and control villages in the postvaccination comparisons for either VT or NVT.

98 Postvaccination concentrations of neutralizing antibodie

99 quency of sepsis symptoms suggests that this postvaccination cytokine pattern may provide some non-M.

100 Postvaccination cytokine responses to CT-B were characte

101 Early postvaccination cytokine secretion and T lymphocyte and

102 ty was assessed on the basis of the ratio of postvaccination (day 22) geometric mean titers (GMTs) be

103 Pre- and postvaccination (day 26-30) serum specimens from 80 VV v

104 A postvaccination decrease in hospitalized community-acqui

105 Previously, we reported postvaccination delayed-type hypersensitivity (DTH) resp

106 recipients, while the removal of skin >12 h postvaccination did not reduce memory in vaccinated mice

107 titers of neutralizing antibodies at 7 days postvaccination (dpv), reaching a plateau at 29 dpv.

108 By 42 days postvaccination (DPV), the majority of pigs had seroconv

109 antitumor immunity as measured by increased postvaccination DTH responses against autologous tumors.

110 ination DTH was the single best predictor of postvaccination DTH.

111 s assessed by a change between pre-study and postvaccination enzyme-linked immunospot frequency of pu

112 In the postvaccination era, anti-HBc seropositivity is a useful

113 and IgG concentrations that persist 2 years postvaccination for all 13 serotypes, regardless of age

114 baseline (T0) and at 7 d (T1) and 28 d (T2) postvaccination for evaluation of immune responses.

115 confidence interval, 2.9%-9.5%) reduction in postvaccination functional antibody titers per year.

116 Furthermore, postvaccination gastritis, likely induced by enhanced ho

117 mmunogenic and ameliorated an observed first postvaccination genital recurrence, but it does not redu

118 cant differences for any influenza strain in postvaccination geometric mean HI or MN titers.

119 tination inhibition seroconversion rates and postvaccination geometric mean titer ratios for each ant

120 TIV induced significantly higher postvaccination geometric mean titers against influenza

121 Prevaccination and postvaccination geometric mean titers were both signific

122 ere was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster

123 to that of TIV on the basis of the ratio of postvaccination GMTs between the 2 vaccines.

124 Pre-and postvaccination granzyme B levels were significantly low

125 in placebo recipients, vaccinees had greater postvaccination H3(Beijing/32) HA (H3)-specific lymphopr

126 cases were less likely than noncases to have postvaccination HAI titers >/=32 or 64.

127 In the first season (2004-2005), postvaccination HAI titers >1:32 were noted for 31.6%, 4

128 In the second season (2005-2006), postvaccination HAI titers >1:32 were seen in 45.5%, 59.

129 d to administration of IIV-SD in both years, postvaccination HAI titers were significantly higher for

130 dies and was readily detectable despite high postvaccination HAI titers.

131 reciated and the mechanisms of NK activation postvaccination have been elucidated.

132 bodies, we generated antigenic maps based on postvaccination hemagglutination inhibition titers again

133 cancer screening, epidemiologic studies, and postvaccination HPV disease surveillance.

134 s over time do not suggest the potential for postvaccination HPV type replacement.

135 idal antibodies in normal, convalescent, and postvaccination human sera is important in understanding

136 elucidate the antibody epitope repertoire in postvaccination human sera.

137 Eleven of 18 postvaccination HZ specimens contained >1 strain, and 7

138 Postvaccination IgA GMCs were 22.1 U/mL, 26.5 U/mL, and

139 Postvaccination IgG anti-HAV were determined at 1, 6, an

140 had significant increases in pre- to 1-month postvaccination IgG levels, but negligible to IgM, and s

141 were recruited to long-term memory 3 months postvaccination, (iii) the most highly expanded effector

142 NK cells contribute to postvaccination immune responses after activation by IL-

143 We then modeled partially effective postvaccination immune status 4 ways: use of PBMCs from

144 e measured the avidities of individual adult postvaccination immunoglobulin G2 (IgG2) antibodies to P

145 In concurrence with these findings, postvaccination immunoglobulin M concentrations were not

146 B may have the potential for causing harmful postvaccination immunologic (Koch-type) reactions.

147 bstantial SBA decay was observed at 6 months postvaccination in both vaccine groups, although more ma

148 Postvaccination incidence of 4vHPV vaccine and nonvaccin

149 weeks postvaccination, < 1 week or > 6 weeks postvaccination), including, respectively, unspecified a

150 oup had reduced prevaccination IgG VH3 and a postvaccination increase in IgG VH5.

151 Postvaccination increases in antitetanus immunoglobulin

152 Postvaccination increases in gamma interferon production

153 in the three study groups combined; however, postvaccination increases in IFN-gamma were significant

154 In addition, postvaccination increases in serum bactericidal activity

155 Significant postvaccination increases in the expression of the VH3 s

156 Humoral responses postvaccination indicate that the vaccine candidate was

157 AIDS vaccines may be critical in determining postvaccination infection outcomes.

158 association between the smallpox vaccine and postvaccination ischemic events, we investigated alterat

159 in capsule-specific immunoglobulin G, with a postvaccination level >or=1000 ng/mL for at least 2 of t

160 Pre- and postvaccination levels of anti-HIV activity were signifi

161 Postvaccination levels of IL-2 were significantly greate

162 Postvaccination lot quality assurance sampling and chron

163 s developed in the 2 onset groups (1-6 weeks postvaccination, < 1 week or > 6 weeks postvaccination),

164 an growth ratio [GR], 9.6; range, 1.3 to 24; postvaccination median GR, 3.9; range, 0.6 to 12.2 [P <

165 throughout 2011 in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.

166 When challenged at 2 wk postvaccination, mice receiving AgDNA or ALM/rIL-12 were

167 vious clinical study, more than one-third of postvaccination nasal wash isolates exhibited partial lo

168 Two years postvaccination, nearly all of the 800 participants (99.

169 ine was judged superior on the basis of mean postvaccination neutralizing antibody titers (12.5 vs. 1

170 Although IL-2-dependent postvaccination NK cell activation has been reported pre

171 ation (P = 0.863), and BLyS levels increased postvaccination only in the subset of patients with BLyS

172 sh were vaccinated and challenged at 70 days postvaccination, only 12% of the IHNV-G-vaccinated fish

173 At 30 days postvaccination, only 5% of fish that had received any o

174 There was good agreement between postvaccination opsonic and IgG antibody levels.

175 oefficient for optical density readings from postvaccination oral fluid compared with serum was 0.81.

176 Male macaques postvaccination (p = 0.018) and postinfection (p = 0.004

177 ination, and 96 during the equivalent period postvaccination (p=0.009).

178 mean titer [GMT], 151 vs. 1010 for pre- vs. postvaccination; P<.001), whereas anti-L1 antibody respo

179 rrelation was noted between tHLA staining of postvaccination PBMC and IFN-gamma expression by the sam

180 We observed that some postvaccination PBMC cultures were less reactive with tu

181 Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treate

182 ative real-time PCR (qRT-PCR) the ability of postvaccination PBMC to produce cytokine in response to

183 e (prevaccination period [PreVP]) and after (postvaccination period [PostVP]) introduction of UMV.

184 7) for all confirmed cases during the 8-week postvaccination period and was 2.75 (95% CI, 1.63-4.62)

185 d, relative risk estimates during the 4-week postvaccination period were 3.02 (95% CI, 1.64-5.56) for

186 All viruses detected during the 2-week postvaccination period were shed vaccine viruses and had

187 s changes in depressive symptoms, during the postvaccination period.

188 s 2.75 (95% CI, 1.63-4.62) during the 4-week postvaccination period.

189 , deaths, and cost-effectiveness over a 30-y postvaccination period.

190 Clustering of onsets within defined postvaccination periods was investigated by the case-ser

191 8 complex) was compared between the pre- and postvaccination periods.

192 that monomeric Env-specific IgA, as part of postvaccination polyclonal antibody response, may modula

193 We determined if the ability of postvaccination, prechallenge sera to enhance SIVmac251

194 Pre- and postvaccination profiles from serum samples of patients

195 Hib-specific sequences, indicating that the postvaccination public BCR repertoire may be related to

196 cimens obtained from vaccine recipients with postvaccination rash or herpes zoster (HZ), focusing on

197 All 21 postvaccination rash specimens contained mixtures of vac

198 Postvaccination rates of seroconversion were greater in

199 Tumor cells from postvaccination resections showed significantly lower TR

200 of 59 (24%) HCWs 10-15, 16-20, and >20 years postvaccination, respectively, (P = ns).

201 %), for the first 3, and subsequent 4+ years postvaccination, respectively.

202 he effect of albendazole pretreatment on the postvaccination response.

203 Pre- and postvaccination responses of HI and neutralizing antibod

204 crease with age, which may lead to different postvaccination responses to emerging influenza variants

205 suggest an age-specific difference in human postvaccination responses.

206 Analysis of the adaptive immune response postvaccination revealed robust specific T- and B-cell r

207 ant relationships were found between several postvaccination rotavirus antibody titers and protection

208 in prevaccination serum samples (Vi) and in postvaccination samples (Vi and rabies).

209 Prevaccination and 6-week postvaccination samples from the immunogenicity substudy

210 ts with or without rgp120 booster, PBMC from postvaccination samples were significantly resistant to

211 At 1 year and 4 years (only for study A) postvaccination, SBA titers were relatively sustained in

212 icantly enhanced when BCG was opsonized with postvaccination sera (P < .01), and these enhancements c

213 d from a densely infiltrated metastasis with postvaccination sera from a long-term responding patient

214 Pre- and postvaccination sera from kidney transplant recipients (

215 pitopes in HA1/HA2 and NA were recognized by postvaccination sera from the two high-dose groups, incl

216 We determined that postvaccination sera increased the uptake of wild-type S

217 Analysis of 793 prevaccination and 800 postvaccination sera indicated that while GMCs were low

218 Using pre- and postvaccination sera of people immunized with the 23-val

219 Effects of prevaccination and postvaccination sera on BCG phagocytosis and intracellul

220 is a fourfold rise in titer between pre- and postvaccination sera or if there is a characteristic boo

221 s reduced as much as 50% when opsonized with postvaccination sera relative to day 0 or placebo serum

222 Typhi when the bacteria were opsonized with postvaccination sera than when the bacteria were opsoniz

223 marker for adequate immune responses if only postvaccination sera were analyzed.

224 The growth-inhibiting effects of postvaccination sera were reversed by preabsorption of I

225 Antigenic maps derived from human postvaccination sera with H1 influenza preexposure also

226 contrast, antigenic maps derived from human postvaccination sera with only type B influenza preexpos

227 oss-reactive bactericidal activity, and some postvaccination sera, was analyzed to determine the spec

228 ased phagolysosomal fusion was observed with postvaccination sera.

229 Frequency of postvaccination seroconversion did not significantly dif

230 infant and contact identification; pre- and postvaccination serologic testing in contacts and infant

231 activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy.

232 Postvaccination serum samples from elderly subjects demo

233 e median age at vaccination was 12.5 months; postvaccination serum samples were obtained on average 4

234 ls was shown to be significantly enhanced in postvaccination serum samples.

235 itulated using immunoglobulins purified from postvaccination serum, demonstrating that antibodies wer

236 rcinogenic HPV types; continued surveillance postvaccination should improve our understanding of the

237 At 10 weeks postvaccination, splenic gamma interferon (IFN-gamma) mR

238 Skin grafts transferred 0 to 24 h postvaccination stimulated a primary immune response in

239 The anti-Hib avidity index postvaccination strongly correlated with the relative fr

240 8(+) T cells were still detected at 5 months postvaccination, suggesting that MVA-H5M provides long-l

241 s obtained during 1550 diarrheal episodes in postvaccination surveillance were rotavirus-positive by

242 vaccination serological survey in 2010 and a postvaccination survey in 2012.

243 verse events through month 13; and solicited postvaccination symptoms through day 7.

244 Solicited postvaccination symptoms were generally mild with more l

245 Magnitudes of pre- and postvaccination T-cell responses were lower in HIV-infec

246 Paradoxically, no increase in postvaccination TCPF was observed in most patients who h

247 reated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02-1.0%), a combination associat

248 ts treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2-2.4% and 0.2-2.5%, respectivel

249 PCR was positive for longer times postvaccination than was SVA.

250 By 3 weeks postvaccination the animals were protected against the e

251 mong the vaccinated animals, but by 7 months postvaccination there was a substantial antigen-specific

252 in part by faster declines with higher peak postvaccination titer.

253 tibody is the major correlate of protection, postvaccination titers alone should not be used as a sur

254 Mean postvaccination titers for individuals who received HD v

255 ly all recipients of inactivated vaccine had postvaccination titers of at least 64, and the small num

256 ain; for those who received SD vaccine, mean postvaccination titers were as 67 for H1N1, 333 for H3N2

257 ralizing antibody titers negatively affected postvaccination titers.

258 sfer of naive 1807 cells at serial intervals postvaccination uncovered the prolonged duration of fung

259 rrence of HZ for >/=1 year (mean, 1.3 years) postvaccination until accrual of >/=96 confirmed HZ case

260 inin antibody inhibition titers from 1 month postvaccination until end-of-study participation.

261 Antibody levels >24 months postvaccination using extended dosing schedules is unkno

262 allenge with the virulent strains at 21 days postvaccination, vaccinated animals showed neither any c

263 cutoff and twofold increase between pre and postvaccination values for <70% of serotypes).

264 sion of Oka VZV from vaccine recipients with postvaccination vesicular rashes was identified in 3 sus

265 Both baseline and postvaccination VZV-specific CMI were lower in the older

266 enerally correlated with higher baseline and postvaccination VZV-specific CMI.

267 D69(+)CD57(+)PD1(+) T cells from baseline to postvaccination was associated with concurrent decreased

268 s based on studies focusing on the immediate postvaccination weeks.

269 measured on both cell types at 2 to 6 weeks postvaccination were comparable to levels observed in na

270 40 plus a >/=4-fold increase over T0 at 3 wk postvaccination were designated as responders.

271 oncentrations before and 8, 32, and 80 weeks postvaccination were determined by plaque reduction neut

272 antigen and challenged intranasally 4 weeks postvaccination were protected against sublethal and let

273 l assays indicated that antibodies generated postvaccination were recognized by complement factors an

274 nst ASFV-G is highly effective after 28 days postvaccination, whereas at 21 days postvaccination, ani

275 e efficacy for HZ BOI persisted into year 10 postvaccination, whereas statistically significant vacci

276 nificantly greater than zero through year 10 postvaccination, whereas vaccine efficacy for incidence

277 ansion in the draining lymph nodes at 6 days postvaccination, which persisted for 2 wk.

278 After the cART interruption at week 12 postvaccination, while total HIV-1 DNA increased signifi

279 inated fish were challenged at 30 or 70 days postvaccination with lethal doses of IHNV.

280 e critically dependent on the length of time postvaccination with the attenuated virus strain, sugges

281 utant and subsequent oral challenge (22 days postvaccination) with the parent revealed a ca. 10,000-f

282 n from lethal challenge was observed by 24 h postvaccination, with 100% protection induced in as litt

283 ects reporting SAEs occurring within 42 days postvaccination (ZV, 0.6%; placebo, 0.5%) and 182 days p

284 ation (ZV, 0.6%; placebo, 0.5%) and 182 days postvaccination (ZV, 2.1%; placebo, 1.9%) was similar be